So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.

The depressed company could use Mylotarg as a stepping stone in AML.